|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 9 (November 1), 1999:
pp. 3062-3066
Coinheritance of the HR2 Haplotype in the Factor V Gene Confers an
Increased Risk of Venous Thromboembolism to Carriers of Factor V
R506Q (Factor V Leiden)
E.M. Faioni,
F. Franchi,
P. Bucciarelli,
M. Margaglione,
V. De
Stefano,
G. Castaman,
G. Finazzi, and
P.M. Mannucci
From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and
Department of Internal Medicine, IRCCS Maggiore Hospital and University
of Milano, Milan, Italy; the Unità di Aterosclerosi e Trombosi,
IRCCS Casa Sollievo della Sofferenza di San Giovanni Rotondo, Foggia,
Italy; the Department of Hematology, Catholic University, Rome, Italy;
the Division of Hematology, S. Bortolo Hospital, Vicenza, Italy; and
the Division of Hematology, Ospedali Riuniti, Bergamo, Italy.
With the aim of establishing whether the HR2 haplotype in factor V
affects the risk of venous thromboembolism, a retrospective multicenter
cohort study was performed in 810 family members identified through 174 probands who suffered from at least 1 episode of deep vein thrombosis
and/or pulmonary embolism and had an inherited defect associated with
thrombophilia (antithrombin, protein C, or protein S deficiency; factor
V R506Q or prothrombin G20210A). Fifty-eight percent (468/810) of the
family members had an inherited defect and 10% (47/468) were
symptomatic. The HR2 haplotype was found in association with factor V
R506Q more frequently in family members with venous thromboembolism
(18%) than in those without (8%). Double heterozygosity for factor V
R506Q and HR2 conferred a 3- to 4-fold increase in the relative risk of
venous thromboembolism compared with factor V R506Q alone. The median
age at first event was lower when the 2 defects were associated (46 v 52 years). No increase in risk of venous thromboembolism
could be demonstrated when the HR2 haplotype was associated with
inherited thrombophilic defects other than factor V R506Q. Because both
factor V R506Q and the HR2 haplotype are very frequent, the effect of
their coinheritance on the risk of venous thromboembolism might
represent a clinically relevant issue, and screening for HR2 in
carriers of factor V R506Q should be considered.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Castoldi, J. M. Brugge, G. A. F. Nicolaes, D. Girelli, G. Tans, and J. Rosing
Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations
Blood,
June 1, 2004;
103(11):
4173 - 4179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Scanavini, D. Girelli, B. Lunghi, N. Martinelli, C. Legnani, M. Pinotti, G. Palareti, and F. Bernardi
Modulation of Factor V Levels in Plasma by Polymorphisms in the C2 Domain
Arterioscler. Thromb. Vasc. Biol.,
January 1, 2004;
24(1):
200 - 206.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Soria, L. Almasy, J. C. Souto, A. Buil, E. Martinez-Sanchez, J. Mateo, M. Borrell, W. H. Stone, M. Lathrop, J. Fontcuberta, et al.
A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility
Blood,
January 1, 2003;
101(1):
163 - 167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Yamazaki, G. A. F. Nicolaes, K. W. Sorensen, and B. Dahlback
Molecular basis of quantitative factor V deficiency associated with factor V R2 haplotype
Blood,
September 18, 2002;
100(7):
2515 - 2521.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Folsom, M. Cushman, M. Y. Tsai, N. Aleksic, S. R. Heckbert, L. L. Boland, A. W. Tsai, N. D. Yanez, and W. D. Rosamond
A prospective study of venous thromboembolism in relation to factor V Leiden and related factors
Blood,
April 15, 2002;
99(8):
2720 - 2725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A.F. Nicolaes and B. Dahlback
Factor V and Thrombotic Disease: Description of a Janus-Faced Protein
Arterioscler. Thromb. Vasc. Biol.,
April 1, 2002;
22(4):
530 - 538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Pastinen, M. Perola, J. Ignatius, C. Sabatti, P. Tainola, M. Levander, A.-C. Syvanen, and L. Peltonen
Dissecting a population genome for targeted screening of disease mutations
Hum. Mol. Genet.,
December 1, 2001;
10(26):
2961 - 2972.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Seligsohn and A. Lubetsky
Genetic Susceptibility to Venous Thrombosis
N. Engl. J. Med.,
April 19, 2001;
344(16):
1222 - 1231.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T C F Sykes, C Fegan, and D Mosquera
Thrombophilia, polymorphisms, and vascular disease
Mol. Pathol.,
December 1, 2000;
53(6):
300 - 306.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
E. Castoldi, P. Simioni, M. Kalafatis, B. Lunghi, D. Tormene, D. Girelli, A. Girolami, and F. Bernardi
Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family
Blood,
August 15, 2000;
96(4):
1443 - 1448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Lane and P. J. Grant
Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease
Blood,
March 1, 2000;
95(5):
1517 - 1532.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A.F. Nicolaes and B. Dahlback
Factor V and Thrombotic Disease: Description of a Janus-Faced Protein
Arterioscler. Thromb. Vasc. Biol.,
April 1, 2002;
22(4):
530 - 538.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
